FDA’s historic approval of PTSD study may boost cannabis sector down the road
FDA’s historic approval of PTSD study may boost cannabis sector down the road
The move marks a rare action by the FDA to sanction a study on cannabis despite the plant’s current Schedule I classification under federal law as a drug with no therapeutic use, in the same category as heroin and LSD.
